Skip to main content

Table 2 Univariate and multivariate analyses of recurrence-free survival (n = 62)

From: Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors

Variable Univariate analysis Multivariate analysis (MTV model) Multivariate analysis (TLG model)
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age (> 60 years vs. ≤ 60 years) 1.88 (0.57–6.19) 0.298     
Sex (men vs. women) 0.62 (0.21–1.85) 0.389     
Site of tumor (gastric vs. non-gastric) 1.19 (0.40–3.57) 0.752     
Size (> 5 cm vs. ≤ 5 cm) 3.83 (1.05–13.98) 0.042*     
Mitotic count per HPFs (> 5 vs. ≤ 5) 4.27 (1.31–13.89) 0.016*     
Resection (R1 vs. R0) 2.48 (0.32–19.45) 0.389     
Modified NIH consensus criteria (high-risk group vs. the other risk groups) 4.67 (1.28–16.98) 0.019* 0.34 (0.05–2.26) 0.261 0.33 (0.048–2.24) 0.255
Adjuvant imatinib treatment (yes vs. no) 4.89 (1.62–14.77) 0.005* 1.28 (0.34–4.77) 0.715 1.39 (0.36–5.35) 0.632
SUVmax (≥ 7.04 vs. < 7.04) 13.46 (2.98–60.75) 0.001* 4.44 (0.79–25.00) 0.091 3.43 (0.53–22.17) 0.196
MTV (≥ 54.76 cm3 vs. < 54.76 cm3) 19.79 (4.37–89.67) < 0.001* 17.69 (2.03–154.17) 0.009*   
TLG (≥ 228.79 g vs. < 228.79 g) 22.24 (4.91–100.77) < 0.001*    20.48 (2.19–191.16) 0.008*
  1. HPF high-power field, SUV standard uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, CI confidence interval
  2. *Bold p value: statistically significant (p < 0.05)